फुफ्फुसाचा कर्करोग (non-small cell)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
कुठे जायचं
भारतातील 12 हॉस्पिटल्स या trial साठी रुग्णांना घेत आहेत.
रजिस्ट्री सारांश (तांत्रिक)
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
स्पॉन्सर: Eli Lilly and Company
NCT06890598 on ClinicalTrials.gov
रजिस्ट्रीवर शेवटचे अपडेट 7 Oct 2026 · आम्ही वाचले 20 Oct 2026